• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 3. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 4. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293
• 5. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Indoles

Recent Advances in the Study of 2-Methyl-1H-indole-3-carbonitrile (CAS: 51072-83-4) in Chemical Biology and Pharmaceutical Research

2-Methyl-1H-indole-3-carbonitrile (CAS: 51072-83-4) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in chemical biology and pharmaceutical research. This compound, characterized by its indole core structure with a methyl group at the 2-position and a nitrile group at the 3-position, has been explored for its potential in drug discovery, particularly as a scaffold for the development of novel therapeutic agents. Recent studies have highlighted its role in modulating various biological pathways, making it a promising candidate for further investigation.

One of the key areas of interest in the study of 2-Methyl-1H-indole-3-carbonitrile is its potential as an anti-inflammatory and anticancer agent. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibited potent inhibitory effects on NF-κB signaling, a critical pathway involved in inflammation and cancer progression. The researchers synthesized a series of analogs and evaluated their biological activity, identifying several compounds with significant anti-proliferative effects against cancer cell lines, including HeLa and MCF-7 cells. These findings suggest that 2-Methyl-1H-indole-3-carbonitrile could serve as a valuable lead compound for the development of new anticancer drugs.

In addition to its anticancer properties, 2-Methyl-1H-indole-3-carbonitrile has also been investigated for its antimicrobial activity. A recent study published in Bioorganic & Medicinal Chemistry Letters reported that this compound and its derivatives exhibited broad-spectrum antimicrobial activity against both Gram-positive and Gram-negative bacteria, as well as fungal strains. The study attributed this activity to the compound's ability to disrupt microbial cell membranes and inhibit essential enzymatic processes. These results underscore the potential of 2-Methyl-1H-indole-3-carbonitrile as a scaffold for the development of new antimicrobial agents, particularly in the face of rising antibiotic resistance.

Another notable application of 2-Methyl-1H-indole-3-carbonitrile is in the field of neurodegenerative disease research. A 2022 study in the European Journal of Medicinal Chemistry explored the neuroprotective effects of this compound and its derivatives in models of Alzheimer's disease. The researchers found that certain analogs could effectively inhibit acetylcholinesterase (AChE) and beta-secretase (BACE-1), two key enzymes involved in the pathogenesis of Alzheimer's disease. These findings highlight the compound's potential as a multifunctional agent for the treatment of neurodegenerative disorders.

The synthesis and structural modification of 2-Methyl-1H-indole-3-carbonitrile have also been a focus of recent research. Advances in synthetic methodologies, such as microwave-assisted synthesis and green chemistry approaches, have enabled the efficient production of this compound and its derivatives with high yields and purity. These developments have facilitated the exploration of structure-activity relationships (SARs) and the optimization of pharmacological properties, paving the way for the development of more effective and selective therapeutic agents.

In conclusion, 2-Methyl-1H-indole-3-carbonitrile (CAS: 51072-83-4) represents a promising scaffold in chemical biology and pharmaceutical research, with demonstrated potential in anticancer, antimicrobial, and neuroprotective applications. Continued research into its mechanisms of action, synthetic optimization, and preclinical evaluation will be crucial for translating these findings into clinically relevant therapies. The versatility and biological activity of this compound make it a valuable subject for future studies in drug discovery and development.

• 51072-84-5(1,2-Dimethyl-1H-indole-3-carbonitrile)
• 104681-06-3(3-methyl-1H-Benz[g]indole-2-carbonitrile)
• 26187-28-0(2,4-dimethyl-1H-Pyrrole-3-carbonitrile)
• 55970-05-3(1,2-Dimethyl-3H-benzo[e]indole)
• 57582-31-7(1,2-Dimethylbenzeindole)
• 13006-59-2(3-Methyl-1H-indole-2-carbonitrile)
• 72248-92-1(2-methylquinoline-3-carbonitrile)
• 26187-29-1(2,5-Dimethyl-1H-pyrrole-3-carbonitrile)
• 104681-01-8(2-methyl-1H-Benz[g]indole-3-carbonitrile)
• 1160169-41-4(6-fluoro-2-methyl-1H-Indole-3-carbonitrile)